Glioblastoma, Malignant Glioma
Conditions
Keywords
biomarker, Q cell, Overall survival, Progression-free survival
Brief summary
The purpose of this study is to determine whether Q cells separated from the glioma sample are determinants in treatment response and prognosis of glioma patients
Detailed description
The unique markers of Qcell were screened using the method of genomics and proteomics, then these markers will be qualitatively and quantitatively evaluated in glioblastoma patients by comparing their relationship with overrall survival/progression-free survival and treatment response.
Interventions
None listed
Sponsors
Guangzhou General Hospital of Guangzhou Military Command
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
First Affiliated Hospital of Fujian Medical University
The First Affiliated Hospital of Nanchang University
Capital Medical University
Tianjin Medical University General Hospital
Shenzhen Second People's Hospital
Huashan Hospital
West China Hospital
Xiangya Hospital of Central South University
The First Hospital of Jilin University
First Hospital of China Medical University
Qilu Hospital of Shandong University
Second Affiliated Hospital of Soochow University
Sun Yat-sen University
Guangzhou First People's Hospital
Xi'an Jiaotong University
Southern Medical University, China
Second Affiliated Hospital of Guangzhou Medical University
Nanfang Hospital, Southern Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. \>=18 years old 2. Primary Glioblastoma is newly diagnosed and confirmed histologically 3. Patient is expected to be treated with temozolomide and followed up routinely at the study site. 4. Willing to sign the informed consent
Exclusion criteria
1. Currently enrolled in any other clinical study 2. History of any other malignancies 3. Refusal to give consent 4. No available tumor tissue for IDH analysis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The effect of each single molecular marker of Q cell on progression-free survival | 3-5 days postoperatively | Participating centres collected data and submitted it by Email to the coordinating centre at the Nanfang Glioma Center. 300 patients with glioblastoma will be prospectively enrolled in this study. The unique markers of Q cell which had been screened using the method of genomics and proteomics will be measured and compared with progression-free and overall survival of patients. Regrettably,the markers of Q cell cannot yet be disclosed because of the confidentiality requirement. Progression-free survival (PFS) will be calculated from the day of first surgery until tumor progression, death, or end of follow-up. Overall survival (OS) will be calculated from the day of first surgery until death or end of follow-up. The effect of each single molecular marker on PFS and OS was investigated using the Cox proportional hazards model. |
| The effect of each single molecular marker of Q cell on overall survival | 3-5 days postoperatively | Participating centres collected data and submitted it by Email to the coordinating centre at the Nanfang Glioma Center. 300 patients with glioblastoma will be prospectively enrolled in this study. The unique markers of Q cell which had been screened using the method of genomics and proteomics will be measured and compared with progression-free and overall survival of patients. Regrettably,the markers of Q cell cannot yet be disclosed because of the confidentiality requirement. Progression-free survival (PFS) will be calculated from the day of first surgery until tumor progression, death, or end of follow-up. Overall survival (OS) will be calculated from the day of first surgery until death or end of follow-up. The effect of each single molecular marker on PFS and OS was investigated using the Cox proportional hazards model. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| We will correlate molecular markers of Q cell with other genetic alterations | 3-5 days postoperatively | Other genetic alterations which have been previously reported include isocitrate dehydrogenase mutation, o6-methylguanine-DNA-methyltransferase methylation, 1p19q co-delation, Tumor Protein 53 (TP53) mutation, histone H3.3 (H3F3A) mutations, etc. The Chi-square test will be used to compare the genotype distribution. |
Countries
China
Contacts
Primary ContactSongtao Qi, Doctor
Backup ContactLei Yu, Doctor
Outcome results
None listed